Skip to content
  • Home
  • Journalists
    • Headlines
  • Community
    • Businesses
    • Jobs
    • Learning
    • Marketplace
  • Store
(@)

Trial of Controversial Alzheimer’s Drug Halted After Disappointing Results

Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate Alzheimer’s disease.

Teddy Rosenbluth
Author: Teddy Rosenbluth

Written by

Teddy Rosenbluth

in

Cassava Sciences Inc, Clinical Trials, Decisions and Verdicts, Falsification of Data, Regulation and Deregulation of Industry, Research, Securities and Commodities Violations, simufilam
←At the Brooklyn Academy, Musical Journeys Through Minefields
EV Projects to Get $13 Billion in Federal Loans→

More posts

  • Pure Joy: Photographer Laylah Amatullah Barrayn Captures Her First ESSENCE Festival Of Culture

  • Angry crowd confronts Republican Rep. Mike Flood at Nebraska town hall

  • Rhea Seehorn celebrates her ‘Pluribus’ Emmy nomination as she waits to hear about Carol and the atom bomb

  • Emmy Nominations Analysis: ‘The Pitt’ And ‘Hacks’ Dominance Proves It Helps To Be On A Show Voters Actually Watch

About Us


Support Us

Trademark & Copyright 1998 – 2025 · MOSAEC

  • Facebook
  • Instagram
  • LinkedIn
  • YouTube